Silvia Mappa

Silvia Mappa has extensive experience in the field of medical affairs and clinical development, particularly in the area of onco-hematology. Silvia currently holds the position of Vice President, Global Medicine Development Lead & Medical Affairs Lead, Onco-Haematology at Sobi - Swedish Orphan Biovitrum AB (publ), starting in May 2023. Prior to this, they served as the Senior Medical Director and Global Head Medical Affairs & Clinical Science Onco-Haematology at the same company from September 2022 to May 2023. Silvia also worked as a Medical Director and Global Clinical Development Lead, Haematology at Sobi from October 2020 to September 2022.

Before joining Sobi, Silvia worked at Helsinn Group from January 2017 to October 2020, serving as a Medical Expert Onco-Haematology in the Global Clinical Research & Development department. Prior to that, they worked at Gilead Sciences as a Medical Project Manager in Medical Affairs Oncology from November 2014 to January 2017.

Silvia began their career at Bayer HealthCare in June 2012, where they held the position of Medical Expert in Global Clinical Development Oncology until October 2014. Silvia also gained experience as a Consultant Medical Doctor at Ospedale S. Raffaele in Milan, Italy from October 2008 to March 2012, and as a Hematology Resident at IRCCS Istituto Nazionale dei Tumori Foundation in Milan, Italy from October 2007 to October 2008.

Silvia's earlier experience includes a Hematology Residency at Azienda Ospedaliera Universitaria Careggi in Florence, Italy, where they focused on the management of hematological malignancies and conducted research in lymphoproliferative disorders and chronic myeloproliferative disorders from September 2004 to September 2007.

Silvia Mappa obtained their Diploma di Specializzazione in Hematology from Università degli Studi di Milano in 2008. Prior to that, they completed their Laurea in Medicine and Surgery from Università degli Studi di Firenze in 2004. Silvia also holds a Maturità Classica from Liceo classico Dante Firenze, which they completed in 1998. Additionally, they have obtained certifications such as the HMX Fundamentals/Pro - Drug Discovery and Development from Harvard Medical School in 2023 and a Certificate of Advanced English from the University of Cambridge in 1997.